Immuneering Corporation

NASDAQ:IMRX

1.18 (USD) • At close September 6, 2024
Bedrijfsnaam Immuneering Corporation
Symbool IMRX
Munteenheid USD
Prijs 1.18
Beurswaarde 34,991,012
Dividendpercentage 0%
52-weken bereik 1 - 9
Industrie Biotechnology
Sector Healthcare
CEO Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D.
Website https://immuneering.com

An error occurred while fetching data.

Over Immuneering Corporation

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The

Vergelijkbare Aandelen

Leap Therapeutics, Inc. logo

Leap Therapeutics, Inc.

LPTX

2.81 USD

Champions Oncology, Inc. logo

Champions Oncology, Inc.

CSBR

4.25 USD

Candel Therapeutics, Inc. logo

Candel Therapeutics, Inc.

CADL

6.14 USD

KORU Medical Systems, Inc. logo

KORU Medical Systems, Inc.

KRMD

2.46 USD

Alaunos Therapeutics, Inc. logo

Alaunos Therapeutics, Inc.

TCRT

2.42 USD

TELA Bio, Inc. logo

TELA Bio, Inc.

TELA

2.75 USD

Taysha Gene Therapies, Inc. logo

Taysha Gene Therapies, Inc.

TSHA

2.04 USD

NextCure, Inc. logo

NextCure, Inc.

NXTC

1.42 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)